Tak Yun
National Cancer Center, Republic of Korea · National Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Tak Yun as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:24 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05036434 · Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical CarcinomaNational Cancer Center, Korea · active not recruiting · Adrenocortical Carcinoma · principal investigator
- Ph1NCT04014257 · A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ MalignanciesHandok Inc. · completed · Phase 1, Solid Tumor, Adult · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:24 UTC. The ranking covers the 200 most relevant of 45 PubMed records, and a shared surname and initials can bring in a namesake. All 45 on PubMed
- Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis.Sci Transl Med · 2017862 citationsRCR 35.5
- First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.J Clin Oncol · 2012645 citationsRCR 17.8
- A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer.Clin Cancer Res · 2011145 citationsRCR 3.4
- 105 citationsRCR 11.5
- Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.J Cancer Res Clin Oncol · 201279 citationsRCR 2.1
- Lipidomics study of plasma from patients suggest that ALS and PLS are part of a continuum of motor neuron disorders.Sci Rep · 202162 citationsRCR 4.1
- Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.Clin Cancer Res · 201160 citationsRCR 1.5
- Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma.Clin Cancer Res · 202155 citationsRCR 3.6
- Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.Int J Radiat Oncol Biol Phys · 201154 citationsRCR 1.4
- Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.Cancer Chemother Pharmacol · 201550 citationsRCR 1.4